Claris Ventures

Claris Ventures is an Italian venture capital firm established in 2019, focusing on early-stage investments in high-potential biopharma companies. The firm's first fund, Claris Biotech I, targets innovations that are poised to enter clinical trials within 12 to 24 months. Claris Ventures is particularly interested in therapeutic areas such as oncology, immunology, and rare diseases—sectors that often have significant unmet medical needs. The firm's strategy involves not only providing capital but also offering hands-on support in areas like project management, finance, and strategic development, allowing scientific founders to focus on their research and development. Claris Ventures aims to build value around strong scientific evidence, with a mission to make a substantial impact on patient care. Claris Ventures leverages Italy's robust R&D ecosystem, drawing from local research centers, clinical institutions, and international collaborations. The team, led by Managing Partners Pietro Puglisi and Ciro Spedaliere, includes experienced professionals who are committed to guiding portfolio companies through the critical early stages of development. Some notable companies in their portfolio include NeoPhore, Resalis Therapeutics, and Kither Biotech, which are all working on breakthrough therapies in their respective fields.